Towards global elimination of cervical cancer in all groups of women – Authors' reply

Kate T. Simms; Julia Steinberg; Michael Caruana; Megan A. Smith; Jie Bin Lew; Isabelle Soerjomataram; Philip E. Castle; Freddie Bray; Karen Canfell

doi:10.1016/S1470-2045(19)30236-0

Towards global elimination of cervical cancer in all groups of women – Authors' reply

Kate T. Simms, Julia Steinberg, Michael Caruana, Megan A. Smith, Jie Bin Lew, Isabelle Soerjomataram, Philip E. Castle, Freddie Bray, Karen Canfell

Epidemiology & Population Health

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	e239
Journal	The Lancet Oncology
Volume	20
Issue number	5
DOIs	https://doi.org/10.1016/S1470-2045(19)30236-0
State	Published - May 2019

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(19)30236-0

Cite this

@article{fe4b3f35dd4142c081dba890295bf6cc,

title = "Towards global elimination of cervical cancer in all groups of women – Authors' reply",

author = "Simms, {Kate T.} and Julia Steinberg and Michael Caruana and Smith, {Megan A.} and Lew, {Jie Bin} and Isabelle Soerjomataram and Castle, {Philip E.} and Freddie Bray and Karen Canfell",

note = "Funding Information: KTS, JS, MC, MAS, J-BL, PEC, and KC report grants from the National Health and Medical Research Council. MC is an investigator and KC co-principal investigator on an investigator-initiated trial of cytology and primary HPV screening in Australia (Compass; ACTRN12613001207707 and NCT02328872 ), which is conducted and funded by the VCS Foundation, a government-funded health promotion charity; the VCS Foundation have received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and Ventana, USA. However, neither KC, MC, nor their institution on their behalf (Cancer Council New South Wales) receive direct or indirect funding from industry for Compass Australia or any other project. PEC has received at reduced or no cost HPV tests and assays for research from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. FB and IS declare no competing interests.",

year = "2019",

month = may,

doi = "10.1016/S1470-2045(19)30236-0",

language = "English (US)",

volume = "20",

pages = "e239",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "5",

}

TY - JOUR

T1 - Towards global elimination of cervical cancer in all groups of women – Authors' reply

AU - Simms, Kate T.

AU - Steinberg, Julia

AU - Caruana, Michael

AU - Smith, Megan A.

AU - Lew, Jie Bin

AU - Soerjomataram, Isabelle

AU - Castle, Philip E.

AU - Bray, Freddie

AU - Canfell, Karen

N1 - Funding Information: KTS, JS, MC, MAS, J-BL, PEC, and KC report grants from the National Health and Medical Research Council. MC is an investigator and KC co-principal investigator on an investigator-initiated trial of cytology and primary HPV screening in Australia (Compass; ACTRN12613001207707 and NCT02328872 ), which is conducted and funded by the VCS Foundation, a government-funded health promotion charity; the VCS Foundation have received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and Ventana, USA. However, neither KC, MC, nor their institution on their behalf (Cancer Council New South Wales) receive direct or indirect funding from industry for Compass Australia or any other project. PEC has received at reduced or no cost HPV tests and assays for research from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. FB and IS declare no competing interests.

PY - 2019/5

Y1 - 2019/5

UR - http://www.scopus.com/inward/record.url?scp=85064833659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064833659&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30236-0

DO - 10.1016/S1470-2045(19)30236-0

M3 - Letter

C2 - 31044714

AN - SCOPUS:85064833659

SN - 1470-2045

VL - 20

SP - e239

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 5

ER -

Towards global elimination of cervical cancer in all groups of women – Authors' reply

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this